ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Viral therapy"

  • 2017 American Transplant Congress

    Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.

    M. Pereira,1 F. Silveira,2 G. Papanicolaou,3 A. Langston,4 R. Avery,5 A. Wijatyk,6 J. Wu,6 M. Boeckh,7 F. Marty,8 S. Villano.9

    1Columbia University Medical Center, New York, NY; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4Winship Cancer Institute, Atlanta, GA; 5Johns Hopkins University, Baltimore, MD; 6Shire, Lexington, MA; 7Fred Hutchinson Cancer Research Center, Seattle, WA; 8Brigham and Women's Hospital, Boston, MA; 9Shire (At Time of Study), Wayne, PA

    Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
  • 2017 American Transplant Congress

    Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation.

    P. Klem,1 L. Al-Omar,2 J. Cooper,2 S. Davis,2 J. Gralla,2 D. Choe,1 A. Wiseman.2

    1Pharmacy, University of Colorado, Aurora, CO; 2Nephrology, University of Colorado, Aurora

    Valganciclovir (VGC) is the standard antiviral agent used for the prevention of CMV diseases in moderate and high risk renal transplant recipients, yet the optimal…
  • 2017 American Transplant Congress

    Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.

    T. Rege,1 K. Hatahet,1 A. Gillespie,1 M. Ghanta,1 I. Lee,1 K. Qureshi,1 K. Lau,2 S. Karhadkar,2 A. DiCarlo,2 S. Constantinescu,1 S. Rao.1

    1Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA; 2Surgery, Temple University, Philadelphia, PA

    Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…
  • 2017 American Transplant Congress

    Kidney Transplant Allocation with CMV Matching Reduces CMV Infection and Related Costs.

    J. Lockridge,1 E. Langewisch,2 D. Basuli,1 A. Olyaei,3 C. Shaut,4 D. Norman.1

    1Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; 2Nephrology, University of Nebraska, Omaha, NE; 3Pharmacy, Oregon Health and Sciences University, Portland, OR; 4Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR

    Cytomegalovirus (CMV) infection is a major cause of morbidity, mortality, and shortened graft survival in kidney transplant recipients. Efforts to prevent CMV infection have traditionally…
  • 2017 American Transplant Congress

    Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.

    J. Lockridge,1 E. Langewisch,2 D. Basuli,1 A. Olyaei,3 C. Shaut,4 D. Norman.1

    1Division of Nephrology, Department of Medicine, Oregon Health and Science University, Portland, OR; 2Nephrology, University of Nebraska, Omaha, NE; 3Pharmacy, Oregon Health and Sciences University, Portland, OR; 4Immunogenetics and Transplant, Oregon Health and Sciences University, Portland, OR

    Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…
  • 2017 American Transplant Congress

    Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.

    C. Larsen,1 M. Alseiari,2 S. Chandran,2 F. Vincenti,2 D. Wojciechowski.1

    1Division of Nephrology, Massachusetts General Hospital, Boston, MA; 2Division of Nephrology, UCSF, San Francisco, CA

    IntroductionBK viremia is a common complication following kidney transplantation. In vitro data suggest that inhibition of the mTOR–SP6-kinase pathway prevents expression of early viral genes…
  • 2017 American Transplant Congress

    Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.

    M. Alfares, R. Avery, N. Turki, K. Alfares, S. Mehta, R. Boger, A. Valsamakis.

    Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Pediatric Infectious Disease, Johns Hopkins, Baltimore, MD; Pathology, Johns Hopkins, Baltimore, MD

    Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…
  • 2016 American Transplant Congress

    Potential Biomarkers and Treatment for BK Virus Associated Nephropathy.

    M. Borkar,1 V. Srivastava,2 R. Cunnington,1 T. Sharma,1 L. Tibbles.1

    1Faculty of Mediicne, University of Calgary, Calgary, AB, Canada; 2CSIR-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India.

    Background: BK polyomavirus assoiciated nephropathy (BKVAN) is one of the major complications in renal transplants, and is associated with significant fibrosis It is important to…
  • 2016 American Transplant Congress

    Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.

    J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.

    Medicine, Emory University, Atlanta, GA.

    Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…
  • 2016 American Transplant Congress

    Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents.

    M. Lubetzky,1 S. Chun,1 A. Joelson,1 E. Akalin,1 P. Gaglio,2 G. DeBoccardo.1

    1Transplantation, Albert Einstein College of Medicine, Bronx, NY; 2Hepatology, Columbia Universtiy, New York, NY.

    Background: Hepatitis C infection (HCV) in kidney transplant (KTx) recipients has been shown to be a risk factor for decreased patient and allograft survival. With…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences